Back to Search
Start Over
The future of EPAC-targeted therapies: agonism versus antagonism.
- Source :
-
Trends in Pharmacological Sciences . Apr2015, Vol. 36 Issue 4, p203-214. 12p. - Publication Year :
- 2015
-
Abstract
- Pharmaceutical manipulation of cAMP levels exerts beneficial effects through the regulation of the exchange protein activated by cAMP (EPAC) and protein kinase A (PKA) signalling routes. Recent attention has turned to the specific regulation of EPAC isoforms (EPAC1 and EPAC2) as a more targeted approach to cAMP-based therapies. For example, EPAC2-selective agonists could promote insulin secretion from pancreatic β cells, whereas EPAC1-selective agonists may be useful in the treatment of vascular inflammation. By contrast, EPAC1 and EPAC2 antagonists could both be useful in the treatment of heart failure. Here we discuss whether the best way forward is to design EPAC-selective agonists or antagonists and the current strategies being used to develop isoform-selective, small-molecule regulators of EPAC1 and EPAC2 activity. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01656147
- Volume :
- 36
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Trends in Pharmacological Sciences
- Publication Type :
- Academic Journal
- Accession number :
- 101936522
- Full Text :
- https://doi.org/10.1016/j.tips.2015.02.003